DNA hypermethylation of ESR1 and PGR in breast cancer: Pathologic and epidemiologic associations

Mia M. Gaudet, Mihaela Campan, Jonine D. Figueroa, Xiaohong R. Yang, Jolanta Lissowska, Beata Peplonska, Louise A. Brinton, David L. Rimm, Peter W. Laird, Montserrat Garcia-Closas, Mark E. Sherman

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Improved understanding of the etiology of estrogen receptor-α (ERα)-negative and progesterone receptor (PR)-negative breast cancers may permit improved risk prediction. In vitro studies implicate DNA hypermethylation of the ERα and PR promoters in the pathogenesis of ERα-negative and PR-negative tumors, but results are not definitive. We evaluated 200 invasive breast cancers selected from a population-based casecontrol study. DNA extracted from fixed tumor tissue cores was tested using MethyLight to assess DNA methylation at four CpG islands: ESR1 promoters A and B; PGR promoters A and B; and a CpG shore, ESR1 promoter C. DNA methylation results were compared with levels of ERα and PR, tumor characteristics, and breast cancer riskfactors. We observed mild to moderate DNA methylation levels in most tumors for ESR1 promoters A and B and PGR promoter B, and a few tumors showed mild methylation in PGR promoter A. In contrast, ESR1 promoter C showed a wide range of methylation and was weakly correlated with lower expression levels of ERα (β = -0.26; P < 0.0001) and PR (β = -0.25; P < 0.0001). The percentage of tumors with methylated PGR promoters A and B was significantly higher for tumors with low ERα (A, Fisher's test P = 0.0001; B, P = 0.033) and PR levels (A, P = 0.0006; B, P = 0.001). Our data suggest that the relationships between DNA methylation of ESR1 and PGR promoters and protein expression are weak and unlikely to represent a predominant mechanism of receptor silencing. In contrast to CpG islands, ESR1 promoter C showed a wider range of methylation levels and inverse associations with ERα and PR expression.

Original languageEnglish (US)
Pages (from-to)3036-3043
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume18
Issue number11
DOIs
StatePublished - Nov 2009

Fingerprint

Progesterone Receptors
Estrogen Receptors
Breast Neoplasms
DNA Methylation
DNA
Methylation
Neoplasms
CpG Islands
Carcinogens
Population
Proteins

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

DNA hypermethylation of ESR1 and PGR in breast cancer : Pathologic and epidemiologic associations. / Gaudet, Mia M.; Campan, Mihaela; Figueroa, Jonine D.; Yang, Xiaohong R.; Lissowska, Jolanta; Peplonska, Beata; Brinton, Louise A.; Rimm, David L.; Laird, Peter W.; Garcia-Closas, Montserrat; Sherman, Mark E.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 18, No. 11, 11.2009, p. 3036-3043.

Research output: Contribution to journalArticle

Gaudet, MM, Campan, M, Figueroa, JD, Yang, XR, Lissowska, J, Peplonska, B, Brinton, LA, Rimm, DL, Laird, PW, Garcia-Closas, M & Sherman, ME 2009, 'DNA hypermethylation of ESR1 and PGR in breast cancer: Pathologic and epidemiologic associations', Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 11, pp. 3036-3043. https://doi.org/10.1158/1055-9965.EPI-09-0678
Gaudet, Mia M. ; Campan, Mihaela ; Figueroa, Jonine D. ; Yang, Xiaohong R. ; Lissowska, Jolanta ; Peplonska, Beata ; Brinton, Louise A. ; Rimm, David L. ; Laird, Peter W. ; Garcia-Closas, Montserrat ; Sherman, Mark E. / DNA hypermethylation of ESR1 and PGR in breast cancer : Pathologic and epidemiologic associations. In: Cancer Epidemiology Biomarkers and Prevention. 2009 ; Vol. 18, No. 11. pp. 3036-3043.
@article{93d3225941ce4618892063a712aa7bce,
title = "DNA hypermethylation of ESR1 and PGR in breast cancer: Pathologic and epidemiologic associations",
abstract = "Improved understanding of the etiology of estrogen receptor-α (ERα)-negative and progesterone receptor (PR)-negative breast cancers may permit improved risk prediction. In vitro studies implicate DNA hypermethylation of the ERα and PR promoters in the pathogenesis of ERα-negative and PR-negative tumors, but results are not definitive. We evaluated 200 invasive breast cancers selected from a population-based casecontrol study. DNA extracted from fixed tumor tissue cores was tested using MethyLight to assess DNA methylation at four CpG islands: ESR1 promoters A and B; PGR promoters A and B; and a CpG shore, ESR1 promoter C. DNA methylation results were compared with levels of ERα and PR, tumor characteristics, and breast cancer riskfactors. We observed mild to moderate DNA methylation levels in most tumors for ESR1 promoters A and B and PGR promoter B, and a few tumors showed mild methylation in PGR promoter A. In contrast, ESR1 promoter C showed a wide range of methylation and was weakly correlated with lower expression levels of ERα (β = -0.26; P < 0.0001) and PR (β = -0.25; P < 0.0001). The percentage of tumors with methylated PGR promoters A and B was significantly higher for tumors with low ERα (A, Fisher's test P = 0.0001; B, P = 0.033) and PR levels (A, P = 0.0006; B, P = 0.001). Our data suggest that the relationships between DNA methylation of ESR1 and PGR promoters and protein expression are weak and unlikely to represent a predominant mechanism of receptor silencing. In contrast to CpG islands, ESR1 promoter C showed a wider range of methylation levels and inverse associations with ERα and PR expression.",
author = "Gaudet, {Mia M.} and Mihaela Campan and Figueroa, {Jonine D.} and Yang, {Xiaohong R.} and Jolanta Lissowska and Beata Peplonska and Brinton, {Louise A.} and Rimm, {David L.} and Laird, {Peter W.} and Montserrat Garcia-Closas and Sherman, {Mark E.}",
year = "2009",
month = "11",
doi = "10.1158/1055-9965.EPI-09-0678",
language = "English (US)",
volume = "18",
pages = "3036--3043",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - DNA hypermethylation of ESR1 and PGR in breast cancer

T2 - Pathologic and epidemiologic associations

AU - Gaudet, Mia M.

AU - Campan, Mihaela

AU - Figueroa, Jonine D.

AU - Yang, Xiaohong R.

AU - Lissowska, Jolanta

AU - Peplonska, Beata

AU - Brinton, Louise A.

AU - Rimm, David L.

AU - Laird, Peter W.

AU - Garcia-Closas, Montserrat

AU - Sherman, Mark E.

PY - 2009/11

Y1 - 2009/11

N2 - Improved understanding of the etiology of estrogen receptor-α (ERα)-negative and progesterone receptor (PR)-negative breast cancers may permit improved risk prediction. In vitro studies implicate DNA hypermethylation of the ERα and PR promoters in the pathogenesis of ERα-negative and PR-negative tumors, but results are not definitive. We evaluated 200 invasive breast cancers selected from a population-based casecontrol study. DNA extracted from fixed tumor tissue cores was tested using MethyLight to assess DNA methylation at four CpG islands: ESR1 promoters A and B; PGR promoters A and B; and a CpG shore, ESR1 promoter C. DNA methylation results were compared with levels of ERα and PR, tumor characteristics, and breast cancer riskfactors. We observed mild to moderate DNA methylation levels in most tumors for ESR1 promoters A and B and PGR promoter B, and a few tumors showed mild methylation in PGR promoter A. In contrast, ESR1 promoter C showed a wide range of methylation and was weakly correlated with lower expression levels of ERα (β = -0.26; P < 0.0001) and PR (β = -0.25; P < 0.0001). The percentage of tumors with methylated PGR promoters A and B was significantly higher for tumors with low ERα (A, Fisher's test P = 0.0001; B, P = 0.033) and PR levels (A, P = 0.0006; B, P = 0.001). Our data suggest that the relationships between DNA methylation of ESR1 and PGR promoters and protein expression are weak and unlikely to represent a predominant mechanism of receptor silencing. In contrast to CpG islands, ESR1 promoter C showed a wider range of methylation levels and inverse associations with ERα and PR expression.

AB - Improved understanding of the etiology of estrogen receptor-α (ERα)-negative and progesterone receptor (PR)-negative breast cancers may permit improved risk prediction. In vitro studies implicate DNA hypermethylation of the ERα and PR promoters in the pathogenesis of ERα-negative and PR-negative tumors, but results are not definitive. We evaluated 200 invasive breast cancers selected from a population-based casecontrol study. DNA extracted from fixed tumor tissue cores was tested using MethyLight to assess DNA methylation at four CpG islands: ESR1 promoters A and B; PGR promoters A and B; and a CpG shore, ESR1 promoter C. DNA methylation results were compared with levels of ERα and PR, tumor characteristics, and breast cancer riskfactors. We observed mild to moderate DNA methylation levels in most tumors for ESR1 promoters A and B and PGR promoter B, and a few tumors showed mild methylation in PGR promoter A. In contrast, ESR1 promoter C showed a wide range of methylation and was weakly correlated with lower expression levels of ERα (β = -0.26; P < 0.0001) and PR (β = -0.25; P < 0.0001). The percentage of tumors with methylated PGR promoters A and B was significantly higher for tumors with low ERα (A, Fisher's test P = 0.0001; B, P = 0.033) and PR levels (A, P = 0.0006; B, P = 0.001). Our data suggest that the relationships between DNA methylation of ESR1 and PGR promoters and protein expression are weak and unlikely to represent a predominant mechanism of receptor silencing. In contrast to CpG islands, ESR1 promoter C showed a wider range of methylation levels and inverse associations with ERα and PR expression.

UR - http://www.scopus.com/inward/record.url?scp=72749106092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72749106092&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-09-0678

DO - 10.1158/1055-9965.EPI-09-0678

M3 - Article

C2 - 19861523

AN - SCOPUS:72749106092

VL - 18

SP - 3036

EP - 3043

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 11

ER -